FibroGen (NASDAQ:FGEN) reported Q4 EPS of ($0.70), $0.21 better than the analyst estimate of ($0.91). Revenue for the quarter came in at $34.37 million versus the consensus estimate of $24.05 million.
FibroGen (NASDAQ:FGEN) reported Q4 EPS of ($0.70), $0.21 better than the analyst estimate of ($0.91). Revenue for the quarter came in at $34.37 million versus the consensus estimate of $24.05 million.